Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Accounts Payables (2020 - 2025)

PROCEPT BioRobotics has reported Accounts Payables over the past 6 years, most recently at $17.3 million for Q4 2025.

  • Quarterly results put Accounts Payables at $17.3 million for Q4 2025, up 72.3% from a year ago — trailing twelve months through Dec 2025 was $17.3 million (up 72.3% YoY), and the annual figure for FY2025 was $17.3 million, up 72.3%.
  • Accounts Payables for Q4 2025 was $17.3 million at PROCEPT BioRobotics, up from $11.1 million in the prior quarter.
  • Over the last five years, Accounts Payables for PRCT hit a ceiling of $17.3 million in Q4 2025 and a floor of $2.0 million in Q4 2021.
  • Median Accounts Payables over the past 5 years was $10.1 million (2023), compared with a mean of $9.7 million.
  • Biggest five-year swings in Accounts Payables: soared 362.84% in 2022 and later dropped 26.31% in 2025.
  • PROCEPT BioRobotics' Accounts Payables stood at $2.0 million in 2021, then soared by 362.84% to $9.4 million in 2022, then surged by 43.74% to $13.5 million in 2023, then dropped by 25.68% to $10.0 million in 2024, then surged by 72.3% to $17.3 million in 2025.
  • The last three reported values for Accounts Payables were $17.3 million (Q4 2025), $11.1 million (Q3 2025), and $11.8 million (Q2 2025) per Business Quant data.